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PURPOSE. To investigate morphologic changes of the corneoscleral limbus in glaucoma patients
using laser scanning confocal microscopy (LSCM) and impression cytology (IC).
METHODS. Eighty patients with glaucoma and 20 with dry eye were enrolled; 20 healthy
subjects served as controls. Patients underwent the Ocular Surface Disease Index (OSDI)
questionnaire, tear film break-up time, corneal staining, Schirmer test I, and LSCM of the
limbus. Laser scanning confocal microscopy evaluated the limbal transition epithelium (LTE)
regularity, dendritic cell (DC) density, and palisades of Vogt (POV). Impression cytology was
performed and samples stained with HLA-DR and IL6.
RESULTS. Glaucomatous patients were divided into three groups: Group 1 (40 eyes): one drug;
Group 2 (20): two drugs; and Group 3 (20): three or more drugs. Limbal transition epithelium
regularity was worse, and DC density higher in Groups 2, 3, and dry eyes compared with
Group 1 and controls (P < 0.01). Preserved drugs worsened LTE regularity and induced
higher DC density compared with preservative-free (PF) drugs (P ¼ 0.041; P ¼ 0.004).
Despite typical POV architecture was preserved, signs of inflammation were found in
glaucoma groups. HLA-DR and IL-6 positivity were higher in Groups 2, 3, and dry eye
compared with controls (P < 0.001), and in preserved versus PF drugs (P < 0.05; P < 0.001).
Dendritic cell density and LTE regularity correlated with HLA-DR, IL-6, and OSDI score in
glaucoma groups and dry eyes (P < 0.001).
CONCLUSIONS. Laser scanning confocal microscopy and IC documented antiglaucoma therapy
induced morphologic alterations of limbus, which may play a role in the glaucoma-related
ocular surface disease. Further studies are required to determine if limbal changes affect stem
cell viability.
Keywords: corneoscleral limbus, primary open angle glaucoma, glaucoma therapy, ocular
surface, in vivo laser scanning confocal microscopy, impression cytology
The corneoscleral limbus (CL), which represents one of thecomponents of the ocular surface morphofunctional unit, is
the most crucial structure involved in the maintenance of the
corneal epithelial integrity because hosts the niches for corneal
epithelial stem cells.1 Several conditions may affect the CL
integrity such as ocular surface inflammatory diseases, chemical
burns, aniridia, contact lens wear, infections, surgical proce-
dures, and the use of topical medications.2
In patients with glaucoma, long-term medical therapy leads
to critical modifications of ocular surface structures and
adnexa, including the conjunctiva, conjunctiva-associated
lymphoid tissue, cornea, Meibomian glands, eyelids, and
periocular skin.3–6 To date, the impact of antiglaucoma
medications on CL was only hypothesized by Schwartz and
Holland, who first introduced the concept of the iatrogenic
limbal stem cell deficiency (LSCD).7 The authors observed the
occurrence of LSCD in glaucomatous patients treated with
pilocarpine and beta blockers who previously underwent
surgeries involving the CL. Given that antiglaucoma medica-
tions are known to alter corneal and conjunctival epithelia and
their deep layers,4–6,8 it is likely that their chronic use is
specifically toxic also to the superficial and deep structures of
the limbal region.
Currently, laser scanning confocal microscopy (LSCM) can
noninvasively assess the ocular surface permitting an in vivo
cytology. Laser scanning confocal microscopy was used to
describe limbal features in healthy subjects,9 in contact lens
wearers,10 in dry eye,11 during superior limbic keratoconjunc-
tivitis,12 and to document ocular surface changes in patients
diagnosed with different types of LSCD.13
In glaucoma, LSCM was widely used to describe ocular
surface tissue alterations induced by medical therapy,5,6,8,14,15
the bleb functionality after filtration surgery,16 and transscleral
aqueous humor outflow modifications induced by medical and
surgical approaches.17,18 This imaging technique was also used
to evaluate modifications induced by different IOP-lowering
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formulations on CL in rabbit models.19,20 To date, no previous
study has been specifically focused on studying the CL status in
patients with glaucoma.
We conducted the present study to describe the micro-
scopic features of CL in medically controlled glaucomatous
patients by using LSCM and immunecytology, in order to
elucidate modifications induced by therapy.
MATERIALS AND METHODS
Patient’s Enrollment
This was a case control observational study that adhered to the
tenets of the Declaration of Helsinki. Our institutional review
board (Department of Medicine and Ageing Science, G.
d’Annunzio University of Chieti-Pescara, Chieti, Italy) approved
the project. We examined 80 consecutive Caucasian patients
(80 eyes) with medically controlled POAG, who came to our
attention at the Glaucoma Centre. Twenty age- and sex-
matched patients (20 eyes) with primary or secondary Sjogren
syndrome (SS)-related dry eye (diagnosed according to criteria
reported by the International Dry Eye Workshop)21 referring to
our Ocular Surface Diseases Centre were also enrolled. Twenty
age- and sex-matched healthy Caucasian subjects (20 eyes)
referring to the General Clinic were used as controls. Written
informed consent was obtained from all subjects prior to
enrolment, after explanation of the nature and possible
consequences of the study.
Glaucomatous patients had to respect the following
inclusion criteria: corrected visual acuity greater than or equal
to 8/10, refractive error less than or equal to 3 diopters (D;
spherical-equivalent), mean IOP at the time of diagnosis greater
than or equal to 22 mm Hg and medically controlled at
enrolment (IOP < 18 mm Hg: mean of three measurements
taken at 9 AM, 12 PM, and 4 PM), central corneal thickness
(CCT; Ultrasound pachimetry, Altair; Optikon 2000, Rome,
Italy) ranging from 530 to 570 lm, visual field (VF) test (30-2
test, full-threshold, Humphrey field analyzer II 750; Carl Zeiss
Meditec, Inc., Dublin, CA, USA) showing at least three
contiguous points on the total deviation probability plot at
the less than 2% level, Glaucoma Hemifield Test ‘‘outside
normal limits,’’ and ophthalmoscopic signs of glaucomatous
optic consistent with the VF alterations. Topical therapy had to
be the same in both eyes without variation during the 12
months immediately prior to enrolment.
Exclusion criteria were the followings: history of systemic
or ocular inflammatory diseases, and systemic or topical
therapies in the last 12 months that could have modified the
CL status, previous ocular surgery, laser therapy, ocular trauma,
chemical burn, end-stage glaucoma, pregnancy, and contact
lens wear. History of corneal dystrophy, inflammatory diseases
of the ocular surface, and dry eye prior to glaucoma diagnosis
and initiating treatment were also considered exclusion
criteria.
Patients with dry eye and healthy controls had to show a
best-corrected visual acuity greater than or equal to 8/10, a
refractive error less than or equal to 3 D (spherical equivalent),
mean IOP lower than 18 mm Hg, CCT ranging from 530 to 570
lm, absence of glaucomatous optic neuropathy, and a normal
VF examination. At the moment of enrolment patients with dry
eye were treated with lubricants five to seven times a day
(preservative-free [PF] hypotonic solution of sodium hyaluro-
nate) and did not receive topical steroids during the last 3
months. Exclusion criteria for dry eye patients were the
followings: lymphoma, AIDS, sarcoidosis, diabetes mellitus;
corneal dystrophy and nondry eye–related ocular surface
inflammatory diseases; systemic or topical therapy with
medications having potential corneal toxicity; diagnosis of
glaucoma; topical therapy with steroids or NSAIDs; contact
lens use; and previous ocular surgery.
None of the healthy subjects had either a history of topical
or systemic therapy nor were they affected with any ocular or
systemic diseases in the last 12 months. Pregnant women and
contact lens wearers were also excluded. Both eyes were
evaluated in the study, but one eye per subject was randomly
chosen (using a computer generated random number list) for
the statistical analysis.
Patient Clinic Assessment
Each subject underwent a careful slit-lamp examination of both
the anterior and posterior segment of the eye.
Ocular Surface Disease Index (OSDI)
Questionnaire and Tear Film Function Tests
After the enrolment and biomicroscopic examination, all
subjects were asked to complete the OSDI questionnaire and
underwent tear film function tests to assess the clinical status
of the ocular surface. The tear film break-up time (BUT),
Schirmer test I (STI; 30 minutes after BUT measurements), and
corneal staining were performed after the completion of the
OSDI questionnaire. The BUT was recorded as the average of
three consecutive measurements; STI result was expressed as
the length of the strip that was wet after 5 minutes; corneal
staining was evaluated with sodium fluorescein 1% (using the
van Bijsterveld method).
LSCM of the CL
The day after the tear film function assessment, LSCM was
performed using a digital confocal laser-scanning microscope
(HRT III Rostock Cornea Module, diode-laser 670 nm;
Heidelberg Engineering GmbH, Dossenheim, Germany), to
study the superficial and deep structures of the CL.
The confocal laser-scanning device was equipped with a
water immersion objective (633/N.A. 0.95 W; Zeiss, Jena,
Germany) and permitted an automatic z-scan determination of
depth of focus within the CL. Thus, high-contrast digital images
of limbal layers with a field of view of 400 3 400 lm were
acquired. The theoretical confocal section thickness is
approximately 10 lm. This is the slice thickness (voxel),
which is imaged by the confocal microscope to form a 2-
dimensional, pixel-based digital image. The lateral and trans-
verse resolution is 4 lm.
Laser scanning confocal microscopy was carried out under
topical anesthesia with 0.4% oxybuprocaine. Proper alignment
and positioning of the head was maintained with the help of a
dedicated movable-target red fixation light for the fellow eye. A
digital camera mounted on a side arm provided a lateral view of
the eye and objective lens to monitor the position of the
objective lens on the surface of the eye. A drop of 0.2%
polyacrylic gel served as coupling medium between the poly
(methyl methacrylate) contact cap of the objective lens and
cornea. The examination was performed in 8 clock-hour
positions of the limbal area (12, 3, 6, 9, corresponding to
superior, nasal, inferior, or temporal limbus; and the four
intermediate positions between the above points), using a
previously described method.13
Sequential images derived from automatic scans and manual
frame acquisition throughout the limbal area in the scheduled
sectors. The automatic brightness mode was selected during
examination.
The presence of palisades of Vogt (POV) and a progressive
morphologic transition of epithelial cells from the conjunctival
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to the corneal phenotype in the peripheral cornea adjacent to
the limbus, were considered indicators of normal CL anatomy.9
Palisades of Vogt and limbal transition epithelium (LTE) were
considered present when revealed in three or four limbal
quadrants, partially present if revealed in only one or two
sectors, and absent if not detected at all. Normal features of
POV are characterized by hyperreflective linear radial stromal
ridges alternating with columns of basal epithelial cells,
originating from the subconjunctival deep stroma.
The normal LTE consists of conjunctival-type bright
epithelium with indistinct cell boundaries, presenting a gradual
transition toward the corneal epithelium. The demarcation
between the two types of epithelia is generally irregular, with
small islands of corneal epithelial cells dispersed within the
sheet of conjunctival epithelium. An arbitrary grading scale of
0 to 3 was adopted to quantify the regularity of the LTE
considering the following parameters: overall epithelial reflec-
tivity, homogeneity of cell shape and size, cell border
demarcation, and evidence of punctate reflective elements
(as presumed sign of inflammation). The overall epithelial
reflectivity was calculated by determining the average gray
value of the image using Image J software (http://imagej.nih.
gov/ij/; provided in the public domain by the National
Institutes of Health, Bethesda, MD, USA). This value corre-
sponded to the sum of gray values of all pixels in the entire
image divided by the number of pixels. An average gray value
less than 60.00 indicated a normal reflectivity, from 60.01 to
75.00 mild reflectivity, 75.01 to 90.00 moderate, and greater
than 90.01 high reflectivity. Therefore, grade 0 corresponded
to the normal aspect, whereas grade 1, 2, and 3 to good,
moderate, and poor degree of regularity, respectively (Fig. 1).
Punctate reflective elements seen in confocal microscopy
are isolated or confluent noncellular hyperreflective spots,
sized approximately from 2 to 6 lm. These elements most
probably correspond to deposition of phlogistic material, such
as mucoproteins or immune complexes, and have been
documented in different ocular surface tissues during inflam-
matory diseases. 6,10,14,22
Limbal dendritic cells (DC) were also examined to
determine their density, at the basal layer and basal membrane
of the limbal epithelium. Dendritic cells can be seen with a
different morphology depending on their maturity. Mature DC
have a slender nucleated cell body from which extends a maze
of long membrane processes resembling dendrites of nerve
cells; immature DC have a large cell body with fewer and
shorter processes, if any. Dendritic cell density (given as cells/
mm2) was calculated, using the analysis software of the
instrument, by averaging numbers of cells from five images
in each position (randomly selected among the recorded
images), counted manually within a region of interest of
standardized dimensions (2503 250 lm).
Eighty images of the CL were acquired (20 for each
quadrant) for each eye; 40 randomly selected high-quality
images (10 for each quadrant) were analyzed. Typical confocal
session lasted 5 minutes and none of the subjects experienced
any visual symptoms or ocular surface epithelial complications
as a result of the examination. A single operator (VF)
performed confocal examinations and selected the images,
which were evaluated by a second operator (LB). Both
operators were masked for the subject history and for
grouping.
Impression Cytology (IC) of the CL
The IC was scheduled to evaluate the expression of HLA-DR
and IL-6 at the transition epithelium of the limbus. These
markers, which can be normally expressed in the normal
conjunctiva,23 are known to be over-expressed in medically
treated glaucomatous patients, and are considered two of the
most prominent inflammatory markers of the ocular sur-
face.24,25 Impression cytology sampling of the LTE was
performed from 36 to 48 hours after confocal microscopy to
avoid misinterpretation due to the mechanical pressure during
execution of LSCM. Each patient received two consecutive
cytological biopsies at the superior-nasal (from 12 to 3 clock-
hour positions) and superior-temporal (from 12 to 9 clock-hour
positions) portions of the LTE, with two different membranes.
Given that these sectors offered a better exposure of areas of
interest, the sampling was easier and thus less bothersome for
the patients. In order to be sure that limbus (and not cornea or
conjunctiva) was precisely impressed during procedure,
membranes were cut in an arched shape (approximately 9-
mm length, 2-mm large) reproducing and matching the limbal
curvature. Samples with cells covering more than 80% of the
membrane area, or samples covering between 50% and 80%
where cells were confluent and present in a defined area of the
membrane (not scattered), were considered suitable for
diagnostic purposes.
For IC the Millicell-CM 0.4-mm membrane (Millipore,
Bedford, Massachusetts, USA) was used and cells were fixed
with cytology fixative (Bio-fix; Bio Optica, Milan, Italy). For
HLA-DR and IL-6 immunofluorescence staining, the Millicell
FIGURE 1. Grading of the LTE regularity at LSCM. (A) Grade 0: normal LTE features (26-lm depth) characterized by homogeneity of cell shape and
size, and normal epithelial reflectivity (58.34). (B) Grade 1: good degree of regularity with LTE features (29 lm) quite similar to grade 0, except for
mild signs of inhomogeneity of cellular size and shape (asterisk), and epithelial hyper-reflectivity (71.35). Punctate reflective elements (arrowhead)
represent signs of inflammation. (C) Grade 2: moderate degree of regularity (30 lm), with more evident sings of epithelial hyperreflectivity (89.00),
presence of punctate reflective elements (arrowhead), inhomogeneity of cellular size and shape (asterisk). (D) Grade 3: poor degree of regularity
(28 lm), characterized by very evident inhomogeneity in cellular size and shape (asterisk), marked epithelial hyperreflectivity (99.75), irregular and
less distinguishable border demarcation, and several punctate reflective elements, sometimes clustered (arrowhead). Scale bar: represents 100 lm.
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membranes were hydrated with distilled water and placed in
80% alcohol for 2 minutes. The membranes were washed in
distilled water and PBS was added for 2 minutes, followed by
two washes with Wash Buffer (Dako, Glostrup, Denmark) of 2
minutes each. Subsequently, filters were incubated with
ribonuclease A (Sigma-Aldrich Corp., St. Louis, MO, USA)
diluted 1:300 in PBS for 25 minutes at room temperature.
Specimens were washed, and protein block (Dako) was added
for 10 minutes at room temperature. Finally HLA-DR antibody
1:50 or IL-6 1:200 (Abcam, Cambridge, UK), both diluted in
antibody diluent (Dako), were incubated overnight at 48C.
Samples were washed and anti-mouse IgG1 Alexa fluor 488
(Invitrogen, San Giuliano Milanese, Italy) for HLA-DR or anti-
rabbit Alexa Fluor 488 (Invitrogen) for IL-6 diluted 1:200, and
propidium iodide at 1:150 (both in antibody diluent; Dako),
were added and incubated for 1 hour at room temperature.
Membranes were mounted with a drop of fluorescent
mounting medium (Dako) and cells visualized with a Zeiss
confocal laser-scanning microscope (510; Carl Zeiss Micro-
Imaging, GmbH, Vertrieb, Germany). Five different fields for
each sample were evaluated, positive (red nucleus and green
cytoplasm) and negative (red nucleus) cells were counted and
the positivity percentage was calculated. Two independent
observers (CC, MF) masked to the details of the staining
technique, performed all evaluations of impression cytology
specimens. Digital images of representative areas were taken.
The presence, features, and the degree of regularity of the
LTE, the presence and features of POV, and the density of
limbal epithelium DC, were the primary outcomes; the
secondary outcomes were the positivity expression of HLA-
DR and IL-6.
Statistical Analysis
The sample size calculation indicated that at least 120 patients
were necessary to have an a of 0.05 and a b of 0.80. Analysis
was performed using SPSS Advanced Statistical 13.0 Software
(Chicago, IL, USA). Student’s t- and v2 tests were used to
evaluate age and sex differences, respectively, between healthy,
glaucomatous, and dry-eye patients. Mann-Whitney U test was
used to determine differences among groups of patients.
Spearman’s correlation analysis was used to investigate the
relations between LSCM parameters and OSDI score, BUT, ST,
and corneal staining and among LSCM parameters. An average
for each patient was used for the statistical analysis. P values
less than 0.05 were considered statistically significant.
RESULTS
The demographic and clinical data of the enrolled subjects are
shown in Table 1. According to the number of antiglaucoma
medications they were taking, glaucomatous patients were
divided into three groups: Group 1 (40 eyes), one drug; Group
2 (20 eyes), two drugs; Group 3 (20 eyes), three or more drugs.
Patient treatment is shown in Table 2. All patients in Group 1
did not modify therapy from treatment onset. More than 90%
of dry-eye patients presented a severity level 2, according to
criteria reported by the International Dry Eye Workshop.21
Ocular Surface Disease Index (OSDI)
Questionnaire and Tear Film Function Tests
Ocular Surface Disease Index questionnaire score, STI, BUT,
and corneal staining were significantly different between
glaucoma groups and controls, and between overall Group 1
compared with Groups 2 and 3 (P < 0.05). Ocular Surface
Disease Index score was significantly different between
preserved and PF drugs (P < 0.05). Dry eyes showed all tests
significantly different with respect to controls and PF drugs
(Group 1; P < 0.05), but not different compared with Groups 2
and 3 (Table 3).
TABLE 1. Demographics and Clinical Data of Healthy Controls, Dry Eye, and Glaucoma Groups
Age, y 6 SD
Sex,
M/F IOP, mm Hg 6 SD MD, dB 6 SD
Mean Time on Therapy,§
mo 6 SD
Healthy controls 55.38 6 4.64 9/11 16.35 6 3.43 1.32 6 0.46 NA
Dry eye 56.63 6 3.66 10/10 15.82 6 2.65 1.65 6 0.35 68.6 6 3.1
Group 1 56.80 6 4.52 20/20 15.63 6 3.70 2.42 6 0.56* 70.2 6 4.5
Group 2 57.28 6 3.53 10/10 13.58 6 2.75 4.45 6 1.03† 66.1 6 3.3
Group 3 58.45 6 4.61 11/9 14.25 6 3.75 6.45 6 1.76‡ 69.5 6 4.2
M, male; F, female; MD, mean defect; NA, not applicable.
* P < 0.05 vs. healthy controls, dry eye, and Groups 2 and 3.
† P < 0.05 vs. healthy controls, dry eye, and Groups 1 and 3.
‡ P < 0.05 vs. healthy controls, dry eye, and Groups 1 and 2.
§ The time on therapy matched with the time of diagnosis.
TABLE 2. Therapy of Glaucomatous Patients
Group Therapy N
Group 1 Single 40
b-blockers 20
Timolol 0.5% (BAK 0.01) 10
PF-timolol 0.5% 10
PGAs 20
Latanoprost 0.005% (BAK 0.02) 10
PF-tafluprost 0.015% 10
Group 2 Double 20
Latanoprost 0.005%-timolol 0.5% fixed combination
(BAK 0.04)
7
Bimatoprost 0.03% (BAK 0.005) and BAK-preserved
timolol 0.5%, unfixed combination
5
Brimonidine 0.2% (BAK 0.05) and BAK-preserved
timolol 0.5%, unfixed combination
4
Dorzolamide-timolol 0.5% fixed combination (BAK
0.0075)
4
Group 3 Triple or more 20
BAK preserved bimatoprost 0.03%, brimonidine and
timolol 0.5% fixed combination (BAK 0.05)
10
BAK preserved latanoprost 0.005%, and dorzolamide
timolol 0.5% fixed combination
7
BAK-preserved bimatoprost 0.03%, BAK-preserved
brimonidine 0.2%, and dorzolamide-timolol 0.5%
fixed combination
3
PGAs, prostaglandin analogs; BAK, % (mg/mL).
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Confocal Microscopy of the CL
Laser scanning confocal microscopy was able to show the
distinct morphology of the limbal structures in all examined
subjects; reliable images of the analyzed quadrants were
obtained in all cases. For all considered parameters there were
no significant differences between the explored quadrants.
Limbal Transition Epithelium
Limbal transition epithelium was recognized in all subjects and
preserved the typical architecture (from 15–30 lm of depth).
This structure was observed at least in three quadrants out of
four in all cases. In Group 1, LTE did not show morphologic
differences compared with controls and between drug classes,
even though eyes treated with BAK-preserved formulations
presented some punctate reflective elements compared with
eyes treated with PF drugs. Groups 2 and 3, and dry eyes
showed epithelial cell hyperreflectivity with more numerous
punctate reflective elements, when compared with Group 1
and healthy controls. These features were quite similar
between Groups 2 and 3. In dry eyes morphologic features
did not differ with respect to Groups 2 and 3, except for a
lower evidence of punctate reflective elements. The grade of
regularity of the LTE was significantly worse in Groups 2, 3,
and in dry eyes compared with overall Group 1 and control (P
< 0.05; Table 4). In Group 1, overall patients treated with
preserved drugs showed a worse grade of LTE regularity with
respect to overall patients treated with PF drugs (P < 0.05;
Table 4). When analyzing the different classes of medications,
preserved PGA, and preserved b-blockers presented a worse
LTE regularity compared with PF formulations (P < 0.05; Table
5). The planar reconstructions of the conjunctival-limbus-
cornea transition of the surface epithelia are showed in Figure
2.
Limbal DC
Dendritic cells were found in all enrolled subjects and for the
most part appeared as bright linear elements with dendritic
processes (mature cells) located at the level of the basal layer
and basal membrane of the limbal epithelium (from 30 and 50
lm of depth). Their size was up to 30, 50, and 40 lm in
controls, dry eyes, and overall glaucoma patients, respectively.
In glaucoma groups DC appeared more hyperreflective,
somewhere presented a clustering tendency, and were found
in 80%, 90%, and 95% in Groups 1, 2, and 3, respectively.
Dendritic cell densities were significantly higher in glaucoma
groups and in dry eyes compared with controls (P < 0.001);
overall Group 1 also significantly differed from Groups 2 and 3
(P < 0.05; Table 4). Overall patients taking preserved
medications presented higher DC density compared with
overall patients treated with PF medications and controls (P <
0.05; Table 4). In Group 1, patients taking preserved PGA or ß-
blockers presented higher DC density compared with patients
treated with PF formulations and controls (P ¼ 0.004);
moreover, PF PGA showed a higher DC density compared
with PF b-blockers (P < 0.05; Table 5).
In both glaucomatous and dry-eye patients, scattered
punctate reflective elements were found interspersed between
DC and epithelial cells (Fig. 3).
Palisades of Vogt
Palisades of Vogt preserved the typical architecture and were
recognized in all enrolled subjects, and were most prominent
in the superior and inferior sectors. These structures were
observed at least in three quadrants out of four in all cases.
Groups 2, 3, and dry-eye patients presented a mild hyper-
reflectivity of stromal ridges and higher evidence of punctate
reflecting elements (within stromal ridges or columns of
epithelium) compared with controls and overall Group 1. Dry
eyes showed more punctate reflecting elements with respect
to glaucomatous patients (Fig. 3). No evident morphologic
TABLE 3. Clinical Characteristics of Patients and Controls
OSDIs BUT STI
Corneal
Staining
Controls 8.4 6 3.2* 14.2 6 2.3* 17.9 6 3.8* 0.4 6 1.2*
Dry eye 48.9 6 4.2† 4.2 6 1.5† 5.8 6 1.2† 2.1 6 1.9†
Group 1 13.9 6 2.7jj 10.6 6 1.7jj 10.2 6 2.1jj 1.6 6 1.1jj
PF drugs 9.4 6 2.0‡ 11.1 6 1.9 10.3 6 2.2 1.6 6 1.3
Preserved drugs 18.4 6 2.2§ 10.1 6 1.8 10.2 6 2.3 1.8 6 1.2
Group 2 46.6 6 5.7 3.9 6 1.2 6.7 6 2.3 2.4 6 2.1
Group 3 47.4 6 6.2 3.8 6 1.2 6.2 6 2.1 2.2 6 2.3
* P < 0.05 vs. overall Group 1 (except for OSDIs), Groups 2, 3, and
dry eye.
† P < 0.05 vs. overall Group 1 and healthy controls.
‡ P < 0.05 vs. preserved drugs.
§ P < 0.0.5 vs. controls, dry eye, overall Group 1, Groups 2 and 3.
jj P < 0.05 vs. Groups 2 and 3.
TABLE 4. Confocal and IC Parameters in Healthy Controls, Dry Eye, and Glaucoma Groups
LSCM Parameters IC Parameters
LTE DC Density, Cells/mm2 HLA-DR, % IL-6, %
Controls 0.48 6 0.53* 21.94 6 7.07† 1.95 6 1.46‡ 2.00 6 1.71‡
Dry eye 2.20 6 0.67 66.72 6 17.32 37.10 6 13.56 47.65 6 7.70
Group 1 1.67 6 0.83§ 68.22 6 21.67jj 24.25 6 7.13 35.15 6 13.70
Preserved drugs 1.95 6 0.59# 77.77 6 20.55§ 26.40 6 7.64¶ 39.40 6 13.96**
PF drugs 1.40 6 0.96 58.68 6 18.71 21.85 6 6.26‡ 26.45 6 5.36‡
Group 2 2.45 6 0.59 97.49 6 24.99 35.05 6 8.14 49.40 6 8.55
Group 3 2.85 6 0.47 104.84 6 20.77 42.00 6 5.83 55.00 6 8.03
* P < 0.001 vs. Groups 2, 3, and dry eye; P < 0.05 vs. Group 1.
† P < 0.001 vs. Groups 1–3 and dry eye.
‡ P < 0.001 vs. Group 1 (overall), 2, 3, and dry eye.
§ P < 0.05 vs. PF drugs and controls.
jj P < 0.05 vs. Groups 2 and 3.
¶ P < 0.05 PF drugs.
# P < 0.05 vs. PF drugs.
** P < 0.001 PF drugs.
Morphologic Changes of the Corneoscleral Limbus IOVS j March 2015 j Vol. 56 j No. 3 j 2054
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/Journals/IOVS/933681/ on 10/05/2015
differences were found between drug classes in Group 1, and
between overall Group 1 and controls.
Impression Cytology of the LTE
HLA-DR– and IL-6–positive cells were found in traces in
controls, whereas were clearly observed in glaucomatous and
dry eye patients (Table 4; Fig. 4). In overall Group 1, Groups 2,
3, and dry eyes the cell positivity percentages of both markers
were significantly higher compared with controls (P < 0.001;
Table 4). Significant differences were also found between
overall preserved and overall PF-drugs for both HLA-DR and IL-
6 (P < 0.05 and P < 0.001, respectively); no significant
differences were found between Groups 2, 3, and dry eyes, for
both markers (Table 4). In Group 1, significant differences
were found for both markers between PF PGA and PF ß-
blockers, and between preserved PGA and preserved ß-
blockers (Table 5; Fig. 4).
Spearman’s correlation analysis indicated that limbal DC
density and LTE regularity significantly correlated with HLA-
DR, IL-6, and OSDI score in glaucoma groups and dry eye (P <
0.001).
DISCUSSION
Most of the literature demonstrated that antiglaucoma medica-
tions negatively affect the ocular surface.4,24–26 While the
conjunctiva, cornea, and adnexa have been extensively
studied,3–6,8,14 dedicated analyses of the corneoscleral limbus
are lacking.
Our study showed that the limbus changes morphology in
response to the antiglaucoma therapy. These changes were for
the most part inflammatory, especially in patients treated with
preserved medications or controlled with multitherapy. Thus,
inflammation (alone or combined with allergy or toxicity) can
be hypothesized as the main mechanism involved in the
iatrogenic limbal alterations, as proposed for other ocular
surface structures.5
To date, limited information of the CL status was reported in
researches that investigated the effects of antiglaucoma
medications on conjunctiva and cornea. Baudouin et al.4
observed inflammatory cell infiltration in conjunctival speci-
mens taken close to the limbus, reporting a greater number of
cells in patients receiving preserved timolol compared with
patients receiving PF-timolol. Liang et al.20 observed inflam-
matory cells with LSCM, in the limbal area of rabbit eyes
TABLE 5. Confocal and IC Parameters in Group 1
LSCM Parameters IC Parameters
Drug Class LTE DC Density, Cells/mm2 HLA-DR, % IL-6, %
Controls 0.48 6 0.53* 21.94 6 7.07† 1.95 6 1.46‡ 2.00 6 1.71‡
Dry eye 2.20 6 0.67 66.72 6 17.32 37.10 6 13.56 47.65 6 7.70
Preserved ß-blockers 2.10 6 0.22§ 68.24 6 61.82jj 21.70 6 2.98#,** 27.40 6 7.47¶,**
PF ß-blockers 1.80 6 0.83 26.55 6 8.39¶ 12.60 6 3.74¶ 21.90 6 3.66¶
Preserved PGA 1.60 6 0.54§ 89.58 6 14.67jj 26.80 6 9.33# 46.40 6 16.58¶
PF PGA 1.21 6 1.30 53.86 6 15.31 16.80 6 6.21 41.00 6 11.62
* P < 0.01 vs. all drug classes and dry eye.
†, ‡ P < 0.05 vs. all drug classes and dry eye.
§ P < 0.05 vs. PF ß-blockers and PF PGA.
jj P¼ 0.004 vs. PF drugs and controls.
¶ P < 0.001 vs. PF drugs.
# P < 0.05 vs. PF drugs.
** P < 0.05 vs. preserved PGA.
‡‡ P < 0.05 vs. PF PGA.
FIGURE 2. Planar reconstruction of the LTE. (A) Limbal transmission epithelium in a healthy eye: conjunctival-type bright epithelium with indistinct
cell boundaries, presenting a gradual transition toward the corneal epithelium. The demarcation between the two types of epithelia is irregular, with
small islands of corneal epithelium dispersed within the sheets of conjunctival epithelium. (B) Limbal transmission epithelium in dry eye: the
normal architecture of the LTE is preserved. The epithelium of the small corneal epithelial islands appears hyperreflective; scattered punctate
reflective elements (white arrow) are recognizable around the corneal epithelial islands. (C) Limbal transmission epithelium of Group 3: the normal
architecture of the LTE is preserved, even though the epithelium shows an increased reflectivity and several punctate reflective elements (black
arrow), especially in the conjunctival side of the limbus. White and black arrowhead indicates the conjunctival and corneal side of the limbus,
respectively. Scale bar: represents 100 lm.
Morphologic Changes of the Corneoscleral Limbus IOVS j March 2015 j Vol. 56 j No. 3 j 2055
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/Journals/IOVS/933681/ on 10/05/2015
receiving BAK preserved latanoprost or BAK 0.02%. Similar
modifications were not observed in eyes receiving PF-
tafluprost. These findings were also in line with a study of
Pauly et al.,19 who clearly observed limbal inflammatory cells
after exposure to BAK preserved latanoprost or BAK 0.02%,
but sporadically after exposure to PF-latanoprost, in an acute
rabbit toxicologic model. Zhivov et al.27 reported an increase
of Langerhans cells in the corneal side of the limbus in healthy
humans volunteers after 12-week application of 0.01% BAC
solution. These studies highlighted the potential major role of
BAK in inducing the limbal inflammation.
Our results were consistent with these findings because we
documented a higher limbal inflammation in patients treated
with BAK-preserved medications compared with patients
treated with PF formulations, both with LSCM and IC. In
detail, BAK stimulated the local immune system by activating
and increasing the number of resident DC; moreover, the
presence of punctate reflecting elements within the LTE, the
basal epithelial membrane and the deeper POV represents an
additional sign of inflammation. These punctate reflecting
elements were considered as confocal signs of inflammation,
previously reported within the acinar wall and the interstice of
meibomian glands during inflammatory conditions, such as the
meibomian gland disease and glaucoma therapy.14,22 In our
study, POV were recognized in all healthy subjects. This result
was in agreement with previous evidence,13 but in disagree-
ment with others,28 supporting an interindividual variability of
such structures.29 In patients with glaucoma, despite the
presence and global architecture of POV was not affected by
therapy (probably because of the deep location of palisades),
the presence of punctate reflecting elements at this level
indicated a deep inflammation induced by drugs. These deep
inflammatory modifications, moreover, were in line with
inflammatory signs observed within the superficial limbal
layers. However, one cannot exclude that after decades of
therapy morphologic alterations of POV can also be observed.
These findings suggest the potential role of antiglaucoma
therapy in disturbing the equilibrium of the environment
where limbal stem cells reside. Evidence that the inflammatory
aspects of POV were similar between glaucoma and dry eye,
with the latter being recognized as a potential cause of limbal
stem cell deficiency,30 seems to further support this hypoth-
esis. Francoz et al.31 found that glaucoma medications and dry
eye significantly lowered the limbal epithelial thickness, as
seen with spectral-domain optical coherence tomography (SD-
OCT). They proposed that limbal epithelial thickness might be
intended as a surrogate of the limbal stem cells status since it
appears to directly correlate and represent the stem cell
density.32 To further support this hypothesis, Lin et al.33
reported that the instillation of BAK 0.5% four times per day for
4 weeks in a mouse model induced the typical manifestations
of LSCD, including corneal neovascularization, severe inflam-
mation in the stroma, and diffuse epithelial defect.
FIGURE 3. Dendritic cells distribution and features of POV at LSCM. (A, B) Dendritic cells distribution in healthy and dry eyes, respectively. (C–F)
Dendritic cells distribution in Group 1 (PF-b-blocker; PF-PGA; preserved b-blocker; preserved PGA). (G, H) Dendritic cells distribution in Groups 2
and 3, respectively. DC show a dendritic shape (black arrowheads), and are significantly more represented in dry eye, and Groups 2 and 3; in
Group 1 DCs are slightly, but significantly more represented in patients taking preserved medications. Punctate reflective elements appear
interspersed between DCs, increasing in glaucoma groups (arrowheads). palisades of Vogt (taken at superior quadrants) showed linear radial
stromal ridges (asterisk) more hyperreflective in Groups 2, 3, and dry eye; also punctate reflective elements were more commonly observed in
Groups 2, 3, and dry eye (arrowheads; [I] healthy controls; [J] dry eye; [K–N] Group 1: PF-b-blocker; PF-PGA; preserved b-blocker; preserved PGA;
[O, P] Groups 2 and 3, respectively). Scale bar: represents 100 lm.
FIGURE 4. HLA-DR and IL-6 immune staining of the LTE. Top line: IL-6 expression positivity; bottom line: HLA-DR expression positivity. (A, I)
healthy eyes; (B, J) dry eye; (C–F) and (K–N) Group 1: PF-b-blocker; PF-PGA; preserved b-blocker; preserved PGA; (G, H) and (O, P) Groups 2 and 3,
respectively. The cytoplasmic positivity (green) of both markers are significantly more expressed in Group 1 taking preserved drugs, Groups 2, 3,
and dry eye compared with Group 1 taking unpreserved drugs and controls. Nuclei of cells were stained with propidium iodide (red). Magnification
3630.
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The mechanisms leading to POV alterations in glaucoma
were not previously considered and, therefore, are unknown;
nevertheless, inflammatory processes occurring within limbal
epithelium and diffusing for contiguity in depth finally reaching
POV, may be hypothesized.
In accordance with reports focused on other ocular surface
structures, patients receiving PF drugs better preserved limbal
morphology at LSCM, confirming the better ocular surface
tolerability of medications without preservative.3,6,8,14,15 How-
ever, DC density and immunoinflammatory marker positivity
were higher in patients receiving PF medications compared
with controls. The control subjects presented values in
accordance with those previously reported.34,35 This suggested
the presence of a mild to moderate limbal inflammation also
when using PF formulations, which was in accordance with
previous observations.24 In addition, our results also suggested
that inflammation might be the first step in the cascade of
limbal alterations, since the inflammatory parameters, such as
DC density, HLA-DR and IL-6 positivity, were the main aspects
that differentiated Group 1 from controls. In Group 1, we
found a higher inflammatory activity of PGA on limbus with
respect to b-blockers at both LSCM and IC. These results reflect
the inflammatory nature of PG, and appear in line with
modifications occurring to other structures such as Meibomian
glands, which presented a pattern of interstitial inflammation
slightly more evident in eyes treated with PF-PGA compared
with eyes treated PF-b-blockers.14
Overall, the inflammatory changes were more pronounced
in patients in multitherapy, and were quite similar to those
observed in patients with dry eye. In detail, density of DC did
not differ between multitreated glaucoma and dry-eye patients,
suggesting that antiglaucoma drugs induced an activation of
the local immune system similar to that observed in dry eyes.
This was also confirmed by the immune-inflammatory marker
positivity and scores of clinical parameters, which did not
differ between multitreated glaucomatous patients and dry
eyes. However, whether limbal modifications depends on the
known primary toxicity of medications versus ocular sur-
face,3–6,8 or are a consequence of the iatrogenic dry eye cannot
be ascertained. The increase of limbal DC and the presence of
punctate reflective elements within the LTE, which are
important in vivo markers associated with ocular surface
diseases leading to dry eye,11,36–38 are shared features.
Evidence that dry eye is one of the possible mechanisms
involved in the development of signs and symptoms of the
glaucoma related ocular surface disease (OSD), further
supports the hypothesis that limbal changes at least in part
could depend on dry eye.39,40
Notably, the significant correlations between DC density,
LTE regularity, HLA-DR, and IL-6 with clinical parameters
indicated that also limbal modifications might take part in the
induction of the glaucoma related OSD.
A remarkable consideration is that worsening of all
considered outcomes was seen from the transition between
one and two drug therapies. The addition of further drugs
did not present statistically significant differences. There-
fore, this result, which was in accordance with recent
reports on Meibomian glands,14 indicates that the addition
of a second drug (and, probably, the higher exposure to
BAK) should be the most pondered step in therapy
evolution.
Some limitations of this study have to be pointed out. First,
this is a cross-sectional study with a similar duration of disease
in all groups: thus, it is unknown the progressive order of
morphologic changes during time. Second, we did not
include control groups receiving vehicles at different BAK
concentrations, which would have been useful in the
definition of the exact role of preservative and active
compounds in limbal modifications. However, in humans this
arises ethical concerns. Third, we cannot identify the initial
site of damage and the first CL modification. Further
prospective studies evaluating the initial CL status in
therapy-na¨ıve eyes, and the impact of medications over time
are warranted to clarify these points.
In conclusion, LSCM identified limbal modifications indi-
cating an increased inflammatory response induced by
antiglaucoma drugs. These modifications, more evident in
patients on preserved or multitherapy, have evident implica-
tions in the overall ocular surface health, considering the
limbus hosts corneal stem cells. Therefore, where available, the
use of PF monotherapy or PF-fixed combinations is advisable.
Further in vivo studies in patients with a longer follow-up
are required to evaluate whether evident macroscopic
morphologic changes of POV occur. In addition, immune-
histology of limbal specimens aimed at assessing stem cell
markers, will clarify the potentiality of antiglaucoma drugs as a
risk factor for limbal stem cell deficiency.
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